9 Meters Biopharma Inc.
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is de… Read more
9 Meters Biopharma Inc. (NMTRQ) - Net Assets
Latest net assets as of March 2023: $-6.30 Million USD
Based on the latest financial reports, 9 Meters Biopharma Inc. (NMTRQ) has net assets worth $-6.30 Million USD as of March 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.31 Million) and total liabilities ($15.61 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.30 Million |
| % of Total Assets | -67.64% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 61.83 |
9 Meters Biopharma Inc. - Net Assets Trend (2019–2022)
This chart illustrates how 9 Meters Biopharma Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for 9 Meters Biopharma Inc. (2019–2022)
The table below shows the annual net assets of 9 Meters Biopharma Inc. from 2019 to 2022.
| Year | Net Assets | Change |
|---|---|---|
| 2022-12-31 | $2.40 Million | -94.23% |
| 2021-12-31 | $41.60 Million | +29.44% |
| 2020-12-31 | $32.14 Million | +434.33% |
| 2019-12-31 | $-9.61 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 9 Meters Biopharma Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 14204230400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2022)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.30K | 0.05% |
| Other Components | $215.01 Million | 8956.57% |
| Total Equity | $2.40 Million | 100.00% |
9 Meters Biopharma Inc. Competitors by Market Cap
The table below lists competitors of 9 Meters Biopharma Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Critical Metals Plc
LSE:CRTM
|
$1.42K |
|
Videndum Plc
LSE:VID
|
$1.42K |
|
A Capital Holding
EGX:ACAP
|
$1.43K |
|
ESPRIT HLDGS - Dusseldorf Stock Exchang
DU:ESHB
|
$1.43K |
|
Alliance Witan Ord
LSE:ALW
|
$1.42K |
|
IMC Exploration Group Public Limited Company
LSE:IMC
|
$1.42K |
|
Unity Metals Limited
AU:UM1
|
$1.42K |
|
OUT
WAR:OUT
|
$1.42K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 9 Meters Biopharma Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2021 to 2022, total equity changed from 41,603,313 to 2,400,543, a change of -39,202,770 (-94.2%).
- Net loss of 43,766,415 reduced equity.
- Other factors increased equity by 4,563,645.
Equity Change Factors (2021 to 2022)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-43.77 Million | -1823.19% |
| Other Changes | $4.56 Million | +190.11% |
| Total Change | $- | -94.23% |
Book Value vs Market Value Analysis
This analysis compares 9 Meters Biopharma Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-4.87 | $0.00 | x |
| 2020-12-31 | $3.14 | $0.00 | x |
| 2021-12-31 | $3.22 | $0.00 | x |
| 2022-12-31 | $0.18 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 9 Meters Biopharma Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1823.19%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 13.81x
- Recent ROE (-1823.19%) is below the historical average (-525.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-26.09 Million |
| 2020 | -191.33% | 0.00% | 0.00x | 1.22x | $-64.71 Million |
| 2021 | -88.40% | 0.00% | 0.00x | 1.21x | $-40.94 Million |
| 2022 | -1823.19% | 0.00% | 0.00x | 13.81x | $-44.01 Million |
Industry Comparison
This section compares 9 Meters Biopharma Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 9 Meters Biopharma Inc. (NMTRQ) | $-6.30 Million | 0.00% | N/A | $1.42K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |